Compare Natera Inc. Common Stock (NTRA) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vanguard S&P 500 ETF — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Vanguard S&P 500 ETF trades at $704.47 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 31.6× Natera Inc. Common Stock's market cap, and Vanguard S&P 500 ETF is more actively traded (4,954,490 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vanguard S&P 500 ETF for 57 Days on average.
| NTRA | VOO | |
|---|---|---|
Market Cap | $57.03B | $1.80T |
Volume | 1,131,157 | 4,954,490 |
Sector | Health | Broad Market / Factor |
52-Week High | $425.64 | $716.17 |
52-Week Low | $179.42 | $580.93 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VOO trades at $715.14 with minimal daily movement, showing strong technical momentum with bullish moving averages. The ETF maintains its position as a core S&P 500 holding with upcoming dividend distribution. Recent news highlights its role in long-term wealth building and recession resilience, though short interest increased 46.9% in September.
VOO offers diversified exposure to large-cap US equities with low expense ratio advantages. Key risks include market-wide volatility and potential earnings growth slowdown from 35% to 15% in 2027. The ETF remains a foundational holding for long-term investors despite near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
